A Disease Management Protocol for Outpatient Perioperative Bridge Therapy with Enoxaparin in Patients Requiring Temporary Interruption of Long-Term Oral Anticoagulation

Pharmacotherapy

Volumn 24, Issue 5 I, 2004, Pages 649-658

  Spyropoulos, Alex C ^a   Jenkins, Patti ^a   Bornikova, Larissa ^a  

^a Lovelace Sandia Health Systems   (United States)

Author keywords

Cost savings; Enoxaparin; Health maintenance organization; Low molecular weight heparin; Oral anticoagulation; Outpatient perioperative bridge therapy

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HEART VALVE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PERIOPERATIVE BRIDGE THERAPY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HEART DISEASES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PERIOPERATIVE CARE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 2342598333     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.6.649.34740     Document Type: Review

References (17)

1. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11.
2. Seo P, Locke CF. Current and potential uses of low molecular weight heparin: a review and economic analysis. Am J Manag Care 2000;6:498-506.
3. Hewitt RL, Chun KL, Flint LM. Current clinical concepts in perrioperative anticoagulation. Am Surgeon 1999;65:270-3.
4. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
5. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999;84:478-80.
6. Montalescot G, Pollet V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000;101:1083-6.
7. Nguyen DPN, Hasson NK. Perioperative management of patients on long-term warfarin therapy. Hosp Pharm 1999;34:103-10.
8. Spyropoulos AC. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Manag Care 2000;6:S1034-44.
9. Spyropoulos AC, Kardos J, Wigal P. Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm 2000;6:298-304.
10. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:S22-38.
11. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low-molecular-weight heparin. Thromb Haemost 1999;82(suppl):62-3.
12. Tinmouth AH, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001;35(6): 669-74.
13. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ 2002;325:925-8.
14. Maharaj S, Bayliff CD, Kovacs MJ. Successful anticoagulation with dalteparin in a patient with mechanical heart valves. Ann Pharmacother 1999;33:1188-91.
15. Anonymous. Home low-molecular-weight heparin bridge therapy in cardiac replacement: safe, effective, and cost-saving. Formulary 2000;35:990-1.
16. Aventis Pharmaceuticals. Lovenox Injection (enoxaparin) package insert. Bridgewater, NJ; 2003.
17. Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 1998;98:1949-84.